The Edmond de Rothschild Investment Partners have announced the closure of its BioDiscovery 4 Venture capital fund for European life science companies. It had raised a total of EUR192 million or USD250 million, which increased by nearly 25% of its investment capacity compared to its previous fund. With the closure of this fund, the total amount raised by the firm reached EUR450 million.

According to Edmond de Rothschild Investment Partners CEO Pierre-Michel Passy, "This is a great achievement for Edmond de Rothschild Investment Partners and its life science tea,. At over EUR190 million, BioDiscovery 4 is our largest European FCPR focused fund so far. The strong support for our existing investors and several new relationships have allowed us to raise the fund in a little more than a year, We see this as a clear recognition for our investment strategy and a recognition of our life science team as expert venture investors."

The fund's investments would be put into therapeutic drug development companies as well as combination medical technology. There will also be investments in molecular diagnostic companies and the fund would invest about EUR20 million per company, most of whom are based in Europe.